cgi-1746 and Toxoplasmosis

cgi-1746 has been researched along with Toxoplasmosis* in 1 studies

Other Studies

1 other study(ies) available for cgi-1746 and Toxoplasmosis

Article	Year
Two small-molecule inhibitors of Frontiers in cellular and infection microbiology, 2023, Volume: 13 Toxoplasmosis caused by. In this study, 152 autophagy related compounds were evaluated as anti-. The results showed that a total of 38 compounds inhibited parasite growth by more than 60%. After excluding the compounds affecting host cell activity, CGI-1746 and JH-II-127 were considered for drug reuse and further characterized. Both CGI-1746 and JH-II-127 inhibited tachyzoite growth by 60%, with IC. Taken together, these findings suggest that both CGI-1746 and JH-II-127 could be potentially repurposed as anti- Topics: Adult; Animals; Cell Proliferation; Humans; Toxoplasma; Toxoplasmosis; Zoonoses	2023

Article

Year

Frontiers in cellular and infection microbiology, 2023, Volume: 13

Toxoplasmosis caused by. In this study, 152 autophagy related compounds were evaluated as anti-. The results showed that a total of 38 compounds inhibited parasite growth by more than 60%. After excluding the compounds affecting host cell activity, CGI-1746 and JH-II-127 were considered for drug reuse and further characterized. Both CGI-1746 and JH-II-127 inhibited tachyzoite growth by 60%, with IC. Taken together, these findings suggest that both CGI-1746 and JH-II-127 could be potentially repurposed as anti-

Topics: Adult; Animals; Cell Proliferation; Humans; Toxoplasma; Toxoplasmosis; Zoonoses

2023